HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR To Consider New Data On Retinol During 2005 Review

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic Ingredient Review Expert Panel plans to re-review retinol and retinyl palmitate during a meeting in June, the panel announced. CIR last reviewed the ingredients in 1987, concluding they are safe for use in cosmetics in concentrations up to 5%

You may also be interested in...



CIR Reopens N-Butyl Alcohol Review To Address Non-Nail Uses

The Cosmetic Ingredient Review Expert Panel is reopening its safety assessment of n-butyl alcohol to create a tentative addendum incorporating the use of the substance in non-nail care formulas, the panel announced during a June 13-14 meeting in Washington, D.C

CIR Reopens N-Butyl Alcohol Review To Address Non-Nail Uses

The Cosmetic Ingredient Review Expert Panel is reopening its safety assessment of n-butyl alcohol to create a tentative addendum incorporating the use of the substance in non-nail care formulas, the panel announced during a June 13-14 meeting in Washington, D.C

CFSAN 2005 Priorities Include Responding To EWG Petition

Responding to a citizen petition from the Environmental Working Group requesting FDA halt the unlawful distribution of misbranded, adulterated and unlabeled cosmetics is an "A" list priority for the agency's Center for Food Safety & Applied Nutrition in fiscal 2005

Related Content

Latest News
See All
UsernamePublicRestriction

Register

RS012668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel